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The Impact of Factor V Mutation on the Risk for Occlusion in Patients
Undergoing Peripheral Vascular Reconstructions
E. S. K. Sampram∗ and B. Lindblad
Department of Vascular Diseases Malmo¨-Lund, Lund University, Malmo¨ University Hospital, Malmo¨, Sweden.
Objective: to determine the impact of Factor V-Leiden on the patency of peripheral vascular reconstructions.
Design: prospective, open and consecutive study.
Methods: a total of 775 patients, who were electively admitted between 1995 and 1997 to the vascular ward unit, were
prospectively analysed for frequency of Factor V-Leiden mutation and patency of reconstruction (one month and one
year). The patients were grouped into carotid, abdominal aortic aneurysm (AAA), renal artery, aortoiliac, infrainguinal,
and venous categories according to procedures and anatomical sites. Post-reconstruction complications and associated
risk factors were also analysed.
Result: in infrainguinal patients Factor V-Leiden was seen in 16% of the patients compared with 10% in the controls.
(Odds ratio 1.60, CI 0.91–2.81). Hypertension, pulmonary disease and smoking were more frequent in individuals without
Factor V-Leiden. Analysing all 775 reconstructions, occlusions were more frequent at one month (14% vs 12%) (p=
0.02) in patients with Factor V-Leiden compared with patients without the mutation. Though this trend was also noted
few patients having infrainguinal reconstructions, the difference was not significant (37% vs 22% (p=0.15) and 46%
vs 27% (p=0.09) after 1 and 12 months, respectively).
Conclusion: factor V mutation (Factor V-Leiden) was more frequent in patients having occluded vascular reconstructions.
Further evaluation is needed.
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Introduction venous thrombosis, the role of Factor V-Leiden muta-
tion as a risk factor for arterial thrombosis is unclear.
The vitamin K-dependent plasma protein. Protein C, The role of Factor V-Leiden in coronary bypass
grafting occlusion has not been established.15 Twowhen activated (Activated Protein C or APC) on endo-
thelial cells by thrombin–thrombomodulin complex, studies of peripheral vascular reconstruction16,17 sug-
gested a lower patency in patients with low APC ratio.inhibits clotting selectively by degrading coagulation
factors Va and VIIIa.1–6 Protein S, also a K vitamin- The aim of this prospective study was to determine
the impact of Factor V-Leiden on the short-term post-dependent plasma protein, functions as a cofactor to
APC. operative thrombotic events (occlusions) in peripheral
vascular reconstructions.Inherited APC resistance is now known to be due
to (Arg506 to Gln) in the Factor V (Factor V-Leiden).4–6
As a result of this mutation one of three APC cleavage
sites is lost, which renders it unavailable as a cofactor
Material and Methodto APC3–6 resulting in the hypercoagulable state. Factor
V-Leiden is found in 20–60% of analysed patients A total of 775 patients undergoing elective vascularwith venous thromboembolism7–11 and in a venous reconstructions between January 1995 and 1997 werethrombosis cohort.12,13 In Malmo¨ the frequency of Fac- prospectively and consecutively included. Clinicaltor V-Leiden is 7–11 in the general population,7,12 but data were entered into the control, Swedish Vascularthere are marked geographical variations.14 Unlike Registry database, SwedVasc.18 DNA analyses to con-
firm Factor V-Leiden was identical using a PCR amp-
lifying technique.19
∗ Please address all correspondence to: E. S. K. Sampram, De- In all 921 different reconstructions were carried outpartment of Vascular Diseases Malmo¨-Lund, Malmo¨ University
Hospital, S-205 02 Malmo¨, Sweden. as follows: carotid, abdominal aortic aneurysm (AAA),
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renal artery, aortoiliacal, infrainguinal, and venous before one month and 102 by one-year follow-up.
Table 1 shows the rate of mortality and frequency ofincluding open and endovascular procedures. This
grouping is in line with the Eurovasc Report 1997.20 Factor V-Leiden among the different groups. Table 2
compares the frequencies of associated risk factors.Operations at different anatomical sites were counted
as separate operations. After a follow-up period of 12 Hypertension (OR 0.62; CI 0.39–0.97), pulmonary dis-
ease (OR 0.43; CI 0.21–0.88) and smoking (OR 0.60; CImonths any procedure at the same anatomical sites
was regarded as a new reconstruction and followed 0.36–0.99) were more frequent in patients without
Factor V-Leiden mutation. Post-reconstruction com-for another 12 months. A patient was recorded as
occluded only once, if occlusion occurred in one or plications (Table 3) showed higher frequency of deep
or graft infection and occlusion/thrombosis in themore reconstructions at the same anatomical site. This
study does not intend to analyse the different index Factor V-Leiden mutation group. At one month there
were few recorded occlusions for carotid, AAA, orprocedures in each category separately.
Follow-up was carried out between February 1995 renal artery patients with or without Factor V-Leiden.
A non-significant tendency for early occlusion in aorto-and December 1998. Patients were called for follow-
up one month and one year after reconstructions. iliac individuals and patients who had infra-inguinal
procedures with Factor V-Leiden was seen (Table 4).During these follow-up periods the patients under-
went clinical status evaluation, noninvasive ex- In the total series occlusion at one month and 1 year
occurred significantly more often in patients with Fac-amination, and angiography if indicated. Function/
patency was recorded as patent-improved, patent- tor V-Leiden: 14% vs 7% and 22% vs 12%, respectively
(Table 4). At one year 148 patients did not undergounchanged, patent but deteriorating, patent-dead,
death as a result of other causes, occluded-improved, follow-up examinations for patency leaving us with
627 original patients of whom 12% (77/627) had Factoroccluded-unchangedoccluded-deteriorating,occluded-
dead. For secondary patency, patients were recorded V-Leiden.
as secondary patency-improved, unimproved, un-
changed or dead. To determine patency/occlusion a
combination of clinical, haemodynamic and an-
Discussiongiographic factors were employed as indicated. All
carotid patients underwent routinely neurologic and
The importance of APC resistance for venous throm-duplex examination within two months after the pro-
bosis is established,21–23 but for arterial thrombosiscedures. All patients undergoing vascular re-
the findings are less certain. Several studies on APCconstruction were started on low molecular weight
resistance and myocardial infarction have not con-heparin before operation and until discharge. After
firmed APC resistance as a risk factor.14,24 Graft oc-discharge most patients continued with antiplatelet
clusion after coronary artery bypass surgery has nottherapy (low dose ASA normally 75–160 mg daily).
been found to be higher in APC-resistant patients thanAssociated risk factors and post-reconstructive com-
in those who are not.15 Results from studies on strokeplications were also analysed and compared among
and APC resistance with or without Factor V-Leidenthe groups. Mortality was controlled by the Swedish
gene analyses are still conflicting.11,24–25 One study,National Death Registry.
evaluating the prevalence of APC resistance in patients
with peripheral vascular disease and correlating the
disorder to outcome after vascular surgery, suggests
Statistical analysis APC resistance as relatively common in patients with
peripheral vascular disease.16 This study also suggests
A comparison within the groups was done with a Yates APC resistance as a risk factor for failure of infra-
corrected Chi-square test. Significance was assumed inguinal bypass. In another study, Donaldson et al.17
when a p-value of less than 0.05 was achieved. Odds suggested, although weakly, like Ouriel et al.,16 a higher
ratio (OR) and 95% confidence interval (CI) were risk of occlusion in infrainguinal reconstructions, but
calculated. found that Factor V-Leiden mutation was not more
prevalent in peripheral vascular surgical patients than
in a control population. In contrast to their findings
we have found, in this analysis and an earlier study,26Results
an increased incidence of the Factor V-Leiden mutation
in patients with infrainguinal, peripheral vascular dis-Twelve percent (93/775) of patients were hetero-
zygotes for Factor V-Leiden (Table 1). Thirty-six died ease. Fisher et al.27 have recently in their studies also
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indicated a greater prevalence of APC resistance in
patients undergoing peripheral arterial bypass grafting
and a trend for APC resistance to be associated with
graft failure.
The lower rate of hypertension, pulmonary disease
and smoking in patients with Factor V-Leiden mutation
must be interpreted cautiously. No other reports to
our knowledge support such an associated pattern.
This prospective study was started to determine if
there existed any differences in the rate of occlusion/
patency after peripheral vascular procedures in
patients with Factor V-Leiden mutation. This study
limits itself to divisions in peripheral vascular re-
constructions to achieve its objectives without delving
into the index procedures separately. We are aware of
the fact that post-reconstruction occlusion is a complex
process involving the type of reconstruction, the run-
off situation, smoking habits, graft material etc. Like-
wise, other abnormalities of the anticoagulant system
besides the Factor V-Leiden, such as hereditary de-
ficiencies of protein C, S, antithrombin III, and the
prothrombin G20210A mutation, could influence the
postreconstructive occlusion rate. Twelve percent of
our patients had Factor V mutation. In a control popu-
lation age matched and from the same area inherited
APC resistance is seen in 7–11%.26 There is a trend of
a higher prevalence of inherited APC resistance in
peripheral vascular surgery patients as a whole with
the exception of those with carotid and renal artery
diseases. A higher prevalence of Factor V-Leiden was
found in infrainguinal patients, 16%, and in venous
patients, 21%. This is in agreement with our previous
findings.26 In this study, we noted a higher occlusion
rate in the subgroup of infrainguinal procedures with
Factor V mutations within the first month (p=0.09) and
one year (p=0.05) after reconstruction. This finding
is supported by other groups.16,17 The increased risk
of occlusion noted in this study in the aortoiliac
and venous groups is in line with other earlier
studies,8,10,12,23 but due to our small number of occluded
reconstructions, this needs to be cautiously evaluated.
Presently, besides poor run-in and run-off, early
graft occlusion (within 30 days) is most often con-
sidered to be the result of technical problems. Graft
occlusion after one month but within one year after
reconstruction has been judged to be a result of graft
stenosis or intimal hyperplasia. APC resistance is now
found in patients with venous thrombosis to be at
least 10 times more common than any other inherited
deficiencies of anticoagulant proteins.7 In patients with
inherited APC-resistance due to Factor V gene muta-
tion, a two-fold risk for early occlusion in lower ex-Ta
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tremity reconstructions was seen in this study. This
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Table 2. Prereconstructive risk factors compared between patients with Factor V-
Leiden and normal Factor V, respectively. (Odds ratio with 95% confidence intervals).
Associated risk Normal Factor Odds
factors Factor V V-Leiden ratio
(n=682) (n=93) (CI)
CVI 180 (26%) 21 (23%) 0.81
0.49–1.36
Diabetes 101 (15%) 14 (15%) 1.02
0.56–1.87
Hyperlipidermia 71 (10%) 11 (12%) 1.15
0.59–2.27
Hypertension 321 (47%) 33 (36%) 0.62
0.39–0.97
Cardiac 269 (39%) 31 (33%) 0.77
0.49–1.21
Earlier vascular surgery 221 (32%) 25 (27%) 0.77
due to atherosclerosis 0.47–1.25
Pulmonary 136 (20%) 9 (10%) 0.43
0.21–0.88
Renal 90 (13%) 10 (11%) 0.79
0.40–1.58
Smoking 233 (34%) 22 (24%) 0.60
0.36–0.99
No risk factors 42 (6%) 6 (7%) 1.05
0.43–2.54
Table 3. Post-operative complications after procedures within 1 month. (Odds ratio
with 95% confidence intervals).
Post-reconstruction Normal Factor Odds
complications Factor V V-Leiden ratio
(n=682) (n=93) (CI)
Bleeding/haematoma 52 (8%) 7 (8%) 0.99
0.43–2.24
Infection (superficial) 31 (5%) 5 (5%) 1.19
0.45–3.15
Infection (deep/graft) 3 (0%) 4 (4%) 10.17
2.24–46.19
Occlusion/thrombosis 41 (6%) 12 (13%) 2.32
1.17–4.59
Cardiac 43 (6%) 9 (10%) 1.59
0.75–3.38
Pulmonary 16 (2%) 1 (1%) 0.45
0.06–3.41
Cerebrovascular insult 14 (2%) 0 —
Amputation 12 (2%) 2 (2%) 1.23
0.27–5.57
Table 4. Comparison of the occlusion rates of patients with normal Factor V and Factor V-Leiden after peripheral vascular procedures
in the different groups.
Type of reconstructions No. and percentage of No. and percentage of No. and percentage of No. and percentage of
occlusions in individuals occlusions in individuals occlusions in individuals occlusions in individuals
with Factor V-Leiden at with Factor V-Leiden at with normal Factor V at with normal Factor V at
1 month 1 year 1 month 1 year
Carotis 0/15 1/12 (8%) 1/162 (1%) 2/127 (2%)
AAA 0/17 0/14 2/109 (2%) 2/84 (2%)
Renal artery 0/4 0/3 0/52 1/32 (3%)
Aortoiliac 2/25 (8%) 3/18 (17%) 8/195 (4%) 22/164 (13%)
Infrainguinal 10/27 (37%) 12/26 (46%) 32/145 (22%) 35/129 (27%)
Venous 1/5 (20%) 1/4 (25%) 3/19 (16%) 4/14 (29%)
Total 13/93 (14%)∗ 17/77 (22%)∗ 46/682 (7%) 66/550 (12%)
∗: p=0.02.
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